Pharma

The LSX Nordic Congress is the leading senior executive strategy, investment and partnering conference for the Nordic region. It has been connecting life science and healthcare industry leaders with international investment and strategic partners to further the growth, development and internationalisation of Nordic life science and healthcare innovation since 2018.

DiscoverBMB is the annual meeting of the American Society for Biochemistry and Molecular Biology. With a mission to share the latest, most impactful research findings in the molecular life sciences, DiscoverBMB offers an exciting agenda that includes talks by the field’s foremost experts, interactive workshops on the latest trends, technologies and techniques, and an invigorating exhibition of posters, services and products. The meeting attracts researchers in academia and industry, educators, trainees and students from across the globe. It offers unparalleled opportunities for collaborating, networking and recruiting.

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge.

With systemic toxicity challenges plaguing the AAV field, low-dose CNS indications are an ideal target for gene therapy. The plethora of neurological indications dominating gene therapy pipelines vary from rare neurological disorders to more common diseases including Parkinson’s, epilepsy and neurodevelopmental disorders. As programs advance globally, the 3rd Annual Gene Therapy for Neurological Disorders Europe meeting is the field’s definitive forum to showcase the European landscape’s progress and specific regulatory challenges. Gene therapy developers from all of the world, including Europe’s brightest minds in CNS gene therapy, will unite in Paris to share their research progress and host an industry-dedicated discussion.

In the context of unprecedented gene therapy investment and clinical progress, with mounting regulatory scrutiny, Gene Therapy Analytical Development Europe will unite innovative biotech and pharma organisations to develop robust analytical tools to guarantee the consistency, quality, and safety of gene therapy products Whether you’re looking for specific characterisation, potency or infectivity approaches to improve your current analytical toolbox or if you’re seeking to understand how gene therapy analytics differ from other biologics you’ve worked on in the past, this focused, technical event will provide insights specifically on the unique analytical challenges posed by gene therapy vectors, delivered by ‘boots on the ground’ scientists grappling with these challenges first-hand. Join 150+ analytical pioneers to discover the realities of working with tools like dPCR, AUC and HPLC, as well as how and where these tools can be most effective in process development, and what the European regulators expect in order to grant approval. Whether you’re working with AAV or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

The Gene Therapy for Muscular Disorders Summit took place in April this year, and is the field’s only industry-focused event specifically designed to help gene therapy developers successfully target the muscle. With a disease-agnostic agenda, but highlighting novel research in Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease and X-Linked Myotubular Myopathy (XLMTM), the expert industry speakers from the likes of Solid Biosciences, Sarepta Therapeutics, Astellas Gene Therapies and Pfizer spent 4-days discussing the fields hottest topics from navigating toxicity to state-of-the-art muscular targeting.

As drug developers are increasingly prioritizing their later stage assets and bringing them through to approval, the Gene Therapy
Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization. Focused specifically on enhancing gene therapy comparability approaches, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to ensure you satisfy regulatory demands and avoid costly delays to clinical programs.

The Gene Therapy Development & Manufacturing Congress delivers in-depth discussion on optimised process strategies and technologies for the successful technical development and manufacture of advanced gene therapy products. Reflecting an industry-wide push towards improved efficacy, safety and commercial viability of gene therapy products, presentations focus on advances in gene editing tools and overcoming challenges.

In the face of evolving regulatory guidelines and mounting scrutiny, Gene Therapy Analytical Development Europe Summit will discuss ways you can apply contemporary analytical tools to guarantee the consistency, quality, and safety of your gene therapy products. We will join leading CMC, regulatory, QC, analytical and process development experts to gain access to novel data and recent case studies by industry professionals from AstraZeneca, the MHRA, Novartis, Sarepta Therapeutics, Roche, Sanofi, and many more.

Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges. If you work in quality control, quality assurance, or process development – we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support. Whether you’re working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.